Tag: antibody-drug conjugate
South Korean Chong Kun Dang Pharm Licenses Synaffix Platform Technology
South Korean's Chong Kun Dang Pharm (CKD) has entered a licensing agreement with Netherlands-based Synaffix for the development of novel antibody-drug conjugates (ADCs) with best-in-class therapeutic index.
BVX001 is Well-tolerated in Preclinical Study – Demonstrating a Favorable Safety...
Results from a preclinical toxicity evaluation study with BVX001, a novel antibody-drug conjugates (ADC) being developed by BiVictriX, showed positive in vivo data when compared to gemtuzumab ozogamicin (Mylotarg™; Pfizer).
First Patient Dosed with PRO1184 and PRO1160 Cleared for Study Initiation...
Dosing has initiated in the Phase 1 first-in-human clinical trial of PRO1184 (NCT05579366), an antibody-drug conjugates or ADC being developed by ProfoundBio comprising a folate receptor alpha-directed antibody conjugated to the exatecan payload using a novel, proprietary hydrophilic linker.
Recent Advances in Antibody-drug Conjugates Produced Using Chemical Conjugation Technology
To date, more than 10 antibody-drug conjugates (ADCs) have been approved by the U.S. Food and Drug Administration (FDA) and contribute to the medical community.
Zai Lab to Commercialize and Expand Patient Access to Tisotumab...
Zai Lab, a patient focused, global biopharma company committed to driving the next wave of healthcare innovation confirmed that it had signed an exclusive collaboration and...
Following Positive Results of Phase III TULIP Trial: FDA Accepts Byondis’...
The U.S. Food & Drug Administration (FDA) has accepted Byondis' submission of a Biologics License Application (BLA) for trastuzumab duocarmazine (previously known as...
HER2, Trastuzumab and the Development of Novel Antibody-drug Conjugates
In the mid-1970s, scientists discovered that certain genes, when mutated, can cause cancer. Based on this observation they theorized that by targeting these oncogenes,...
Sutro’ STRO-002 Receives FDA Fast Track Designation for Patients with Advanced...
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for STRO-002. The investigational drug, being developed by Sutro Biopharma, is a...
Daiichi Sankyo Reaffirms Long-term Goals with Increased Investment in ADCs
With the launch of fam-trastuzumab-deruxtecan-nxki (Enhertu®), Daiichi Sankyo's first antibody-drug conjugates, coupled with a strong pipeline of innovative ADC, the company has established a...
FDA Approves Loncastuximab Tesirine in Treatment of Relapsed or Refractory Diffuse...
Diffuse large B-cell lymphoma (DLBCL), a form of non-Hodgkin lymphoma, is the most common form of blood cancer. Lymphomas occur when cells of the...
